Keyphrases
Human Cells
100%
Combinational Therapy
100%
Familial Dysautonomia
100%
Pridopidine
66%
IKBKAP
50%
Trichostatin A
33%
Kinetin
33%
Sigma-1 Receptor
16%
Additive Effect
16%
Combined Treatment
16%
Autosomal Recessive
16%
Histone Deacetylase Inhibitor (HDACi)
16%
Receptor-mediated
16%
Point mutation
16%
FDA-approved Drugs
16%
Genetic Neuropathies
16%
Therapeutic Value
16%
Food Supplements
16%
5′ Splice Site
16%
Combination Treatment
16%
BDNF Signaling Pathway
16%
Immunology and Microbiology
Signal Transduction
100%
Intron
100%
Point Mutation
100%
Human Cell
100%
Autosomal Recessive Inheritance
100%
Brain Derived Neurotrophic Factor
100%
Neuroscience
Dysautonomia
100%
Phosphatidylserine
100%
IKBKAP
50%
Trichostatin A
33%
Kinetin
33%
Cell Signaling
16%
Brain-Derived Neurotrophic Factor
16%
Histone Deacetylase Inhibitor
16%
Point Mutation
16%
Peripheral Neuropathy
16%
Intron
16%
Sigma 1 Opiate Receptor
16%
Biochemistry, Genetics and Molecular Biology
Phosphatidylserine
100%
Pridopidine
66%
IKBKAP
50%
Trichostatin A
33%
Signal Transduction
16%
Intron
16%
Autosomal Recessive Inheritance
16%
Point Mutation
16%
Brain-Derived Neurotrophic Factor
16%
Histone Deacetylase
16%
Sigma-1 Receptor
16%